在怀孕中产后母性血栓友的检查值,严重的妊娠对于妊娠年龄来说很小
Maëlig Abgral1, Céline Desconclois2, Sophie Prevot3
1Department of Obstetrics and Gynecology, DMU Santé des Femmes et des Nouveau-nés, Antoine Béclère Hospital, Paris Saclay University, Clamart, France.
Acta obstetricia et gynecologica Scandinavica
|May 15, 2025
概括
在严重的妊娠年龄 (SGA) 出生后进行的母体血栓友爱检测显示,阳性结果的患病率很低. 基于病史的有针对性的血栓形成治疗,建议在广泛的分娩后查上进行.
科学领域:
- 产科和妇科 产科和妇科
- 血液学 血液学 血液学
- 新生儿科学 新生儿科学
背景情况:
- 严重的妊娠年龄小 (SGA) 需要对潜在原因进行调查,包括母体血栓友爱症.
- 关于血栓友爱和胎儿生长限制的文献仍然不一致.
- 产后血栓功能检查通常被认为是新生儿的确诊子宫内生长限制没有明确的产前病因.
研究的目的:
- 确定新生儿出生体重在第三百分点以下的母亲血栓友爱症的患病率和类型.
- 为了分析胎盘病理与血栓友状态结合.
- 评估在严重的SGA病例中进行广泛的产后血栓性查的有用性.
主要方法:
- 在一个法国第三级护理中心 (2014-2018) 进行了回顾性观察队列研究.
- 包括患有严重SGA (出生体重<第三百分位) 的活生生的婴儿.
- 收集关于产后血栓友病 (遗传和获得) 和胎盘病理的数据.
主要成果:
- 在733名患有严重SGA的患者中,54.7%接受了产后血栓友爱治疗.
- 遗传性血栓性病的总体患病率为6.7%;获得性血栓性病的患病率为2.0%.
- 异卵性因子V和II突变是最常见的遗传异常;抗脂抗体是罕见的.
结论:
- 在严重的SGA病例中进行广泛的产后血栓友爱查,结果呈阳性结果的比例很低.
- 血栓形成症治疗的处方应以个人和家庭血栓形成病史为指导.
- 对遗传性血栓性和抗脂抗体的测试应遵循既定指南.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
568
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
568
01:24Disorders of Hemostasis
658
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
658
01:07Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K